Sköld v. Galderma Laboratories, L.P.

99 F. Supp. 3d 585, 2015 WL 1740032
CourtDistrict Court, E.D. Pennsylvania
DecidedApril 17, 2015
DocketCivil Action No. 14-5280
StatusPublished
Cited by20 cases

This text of 99 F. Supp. 3d 585 (Sköld v. Galderma Laboratories, L.P.) is published on Counsel Stack Legal Research, covering District Court, E.D. Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Sköld v. Galderma Laboratories, L.P., 99 F. Supp. 3d 585, 2015 WL 1740032 (E.D. Pa. 2015).

Opinion

OPINION

WENDY BEETLESTONE, District Judge.

I. INTRODUCTION

Before the Court are Defendants Gald-erma Laboratories, L.P. and Galderma Laboratories, Inc.’s Motion to Dismiss and Motion to Stay Pending the Outcome of the Administrative Proceeding, Plaintiff Thomas Skold’s Response in Opposition thereto, and Galderma L.P. and Galderma Inc.’s Reply, as well as Defendant Galder-ma S.A.’s Motion to Dismiss and Motion to Stay Pending the Outcome of the Administrative Proceeding, the Plaintiffs Response in Opposition thereto, and Galder-ma S.A.’s Reply.1 The Court held oral argument on all pending motions on March 19, 2015.

For the reasons that follow, the motion to stay shall be denied as moot, the motions to dismiss for failure to state a claim shall be granted in part, and the motion to dismiss for lack of personal jurisdiction shall be denied.

II. FACTUAL HISTORY AND PROCEDURAL BACKGROUND

According to the facts alleged in the Complaint, Plaintiff Thomas Skold is a citizen of Sweden. Compl. ¶4. Defendant Galderma S.A. (“S.A.”) is a Swiss corporation with its principal place of business in Switzerland, while Defendant Galderma Laboratories, Inc. (“Inc.”) is a Delaware corporation with its principal place of business in Texas and Defendant Galderma Laboratories, L.P. (“L.P.”) is a Texas limited partnership with its principal place of business in Texas. Id. ¶¶ 5-7. All three Defendant entities are “involved in the research, development, marketing, and sale of pharmaceutical and therapeutic skin care products.” Id. Skold alleges that S.A. is the ultimate owner of both Inc. and L.P. Id. ¶ 8.

In Summer 2001, Skold began developing the technology that would eventually become known as “Restoraderm” and set out to find entities interested in licensing the technology and developing the resulting product to be marketed and distributed for mass consumption. Id. ¶ 11. In September 2001, Skold met with Collage-nex Pharmaceuticals, Inc. (“Collagenex”) of Newtown, Pennsylvania, and presented it formulations of his Restoraderm technology, using the phrase “Restoraderm technology” both in his oral presentation and written materials. Id. ¶ 12. Skold used the term “Restoraderm” in similar meetings he had with other pharmaceutical companies throughout the remainder of 2001. Id. ¶¶ 14-18. He first manufactured a Restoraderm product “in its current form in about October 2001,” and delivered samples of a material with the [592]*592“Restoraderm” label to Collagenex in November and December 2001 and January 2002. Id. ¶¶ 19-21. Skold and Collage-nex executed a Letter of Intent in December 2001 and signed a Cooperation, Development, and Licensing Agreement on February 11, 2002 (the “2002 Agreement”). Id. ¶¶ 22-23. Under the 2002 Agreement, Skold continued developing the Restoraderm technology, while Colla-genex developed and maintained the Res-toraderm intellectual property rights, including registering and protecting the “Restoraderm” trademark, a process Col-lagenex began in 2002. Id. ¶¶ 24-26. '

In August 2004, Skold and Collagenex signed a Consulting Agreement under which Skold would provide “technical consulting and development services with respect to Restoraderm Technology in such manner as shall be requested by the Company from time to time,” defining “Resto-raderm Technology” as the “topical drug delivery technology developed by Skold.” Id. ¶ 28. On August 19, 2004, Skold and Collagenex restructured the 2002 Agreement into an Asset Purchase and Product Development Agreement (the “2004 Agreement”), which “formalized Skold’s control of the Restoraderm development.” Id. ¶¶ 27, 29. In the course of negotiating this agreement, Collagenex “confirmed” that the Restoraderm trademark was included in the assets contemplated in the agreement. Id. ¶ 30.

Inc. acquired Collagenex in March 2008 and terminated the 2004 Agreement with Skold on November 27, 2009. Id. ¶¶ 33-34. Section 8.5(b) of the 2004 Agreement provides that should Collagenex terminate the Agreement, the assets, including the Restoraderm intellectual property, and additional related records shall be transferred to Skold. Id. ¶ 35 & Ex. A at 19. Skold alleges that the “parties’ contractual intent was that the Restoraderm trademark would be returned to Skold if the 2004 Agreement were cancelled by Colla-genex (or its successors-in-interest),” but that the Defendants have yet to return the Restoraderm trademark to Skold in accordance with this provision. Id. ¶¶ 36-37.

After terminating the 2004 Agreement, Skold alleges the Defendants “gave mixed messages” regarding their intentions for future use of the Restoraderm trademark and Restoraderm technology. Id. ¶ 38. On September 14, 2010, L.P. issued a Press Release announcing the launch of “Cetaphil® Restoraderm® products” in the United States, which, according to the Complaint, “made it clear that the Defendants intended to use the mark ‘Restora-derm’ in connection with a product to be sold by them in the United States.” Id. ¶¶ 39-40. Skold alleges ' that this press release “was the first time that the Defendants had used the term ‘Restoraderm’ in connection with a U.S. product that did not involve Skold’s Restoraderm technology.” Id. ¶ 43.

Skold filed an action in this Court on September 15, 2014, alleging three counts under the Lanham Act — trademark infringement, false advertising, and unfair competition- — and three counts under Pennsylvania state law — unfair competition, breach of contract, and unjust enrichment. Id. ¶¶ 48-80. Skold previously initiated a proceeding before the U.S. Patent and Trademark Office seeking to cancel the Defendants’ registration of the “Resto-raderm” trademark, id. ¶ 37, but that proceeding has been stayed by the Trademark Trial and Appeal Board (“TTAB”) pending the outcome of this litigation. See infra Section IV.A.

L.P. and Inc. filed a motion to dismiss on December 1, 2014. They contend as follows. First, the breach of contract and unjust enrichment claims are barred by Pennsylvania’s four-year statute of limita[593]*593tions because the claims began to accrue prior to September 15, 2010. Second, the breach of contract claim should also be dismissed for failing to comply with the agreement’s dispute resolution and mediation clause. Third, the unjust enrichment claim should be dismissed because the complained-of conduct is governed by contract, which precludes Skold from availing himself of quasi-contract theories of recovery. And finally, the unfair competition claim is precluded by the gist of the action doctrine because he impermissibly attempts to recast a breach of contract claim as a tort claim. See L.P./Ine. Mot. to Dismiss at 8-9.

On December 22, 2014, Skold filed his response in opposition. He argues that he filed the Complaint within the four-year limitations period because he was unaware the contract was breached until September 14, 2010, when L.P. issued the press release announcing the Restoraderm product. In the alternative, Skold contends he is entitled to equitable tolling of the statute of limitations. Furthermore, he argues that the unjust enrichment claim is not precluded against all parties by the contract and the gist of the action doctrine does not bar his unfair competition claim. See Pl.’s L.P./Ine. Opp’n at 10-13. In reply, L.P. and Inc.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

GABRIEL v. DSM BIOMEDICAL, INC.
E.D. Pennsylvania, 2025
QIAN v. AiYaYa
W.D. Pennsylvania, 2025
REN v. AilunUS
W.D. Pennsylvania, 2025
YANUSHEVSKAYA v. AFLYKO
W.D. Pennsylvania, 2025
BEMCY LLP v. GILEAD SCIENCES INC
E.D. Pennsylvania, 2022
PNC EQUIPMENT FINANCE, LLC v. PAK
E.D. Pennsylvania, 2020
Britax Child Safety, Inc. v. Nuna Int'l B.V.
321 F. Supp. 3d 546 (E.D. Pennsylvania, 2018)
Peterson v. Evapco, Inc.
188 A.3d 210 (Court of Special Appeals of Maryland, 2018)
Wiggins v. Physiologic Assessment Services, LLC
141 A.3d 1058 (Superior Court of Delaware, 2016)
in Re: Giant Eagle, Inc.
Court of Appeals of Texas, 2015
Wen v. Willis
117 F. Supp. 3d 673 (E.D. Pennsylvania, 2015)

Cite This Page — Counsel Stack

Bluebook (online)
99 F. Supp. 3d 585, 2015 WL 1740032, Counsel Stack Legal Research, https://law.counselstack.com/opinion/skold-v-galderma-laboratories-lp-paed-2015.